Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory molecular profiling study of Japanese patients treated with brodalumab (ESPRIT)
jRCTs041190114Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of brodalumab in plaque psoriasis, sponsored by Kyowa Kirin. Primary endpoints: PASI score at 12 weeks, PASI score 0 achievement rate at 12 weeks and 2 more. Started Mar 2020; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCTs041190114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190114.